Immunotherapy in Non-muscle-invasive Bladder Cancer: Current Status and Future Directions

Overview

Journal World J Urol

Specialty Urology

Date 2020 Oct 15

PMID 33057888

Citations 23

Authors

John L Pfail

Andrew B Katims

Parissa Alerasool

John P Sfakianos

Affiliations

Soon will be listed here.

Abstract

Purpose: Patients harboring high-grade non-muscle-invasive bladder cancer (NMIBC) experience high rates of both recurrence and progression. Currently, few treatment options besides cystectomy exist for this at-risk population, especially those with BCG-unresponsive disease. The purpose of this review is to present the current status and describe future directions of immunotherapy in NMIBC.

Methods: The PubMed and Google Scholar databases were searched for articles pertaining to immunotherapy in NMIBC. Relevant planned and ongoing clinical trials were identified using www.ClinicalTrials.gov . Published randomized control trials, reviews, other retrospective and prospective studies deemed relevant were used in this review paper.

Results: Novel immunotherapies used in the treatment of high-grade NMIBC and BCG-unresponsive disease allow patients more options and have the potential to reduce the need for radical cystectomy. Currently, several options target the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis as this mechanism of immunotherapy has been shown to be effective in several cancers, including bladder, melanoma, and lung cancers. In addition, other immunotherapy options for the treatment of NMIBC include viral gene therapies, interleukin-15 superagonists, small molecule inhibitors of indoleamine (2,3)-dioxygenase 1, and vaccines.

Conclusions: The current landscape of immunotherapy in bladder cancer is rapidly evolving, with much literature pertaining to muscle-invasive and metastatic disease. However, the implementation of these treatment options in high-grade NMIBC may allow patients to avoid life-altering surgery. Reliable biomarkers for response are needed to further select patients who may benefit from such therapies.

Citing Articles

CDCA4 promotes bladder cancer progression by JAK/STAT signaling pathway.

Wan P, Ren Y, Deng H, Li H J Cancer Res Clin Oncol. 2025; 151(2):46.

PMID: 39856473 PMC: 11762220. DOI: 10.1007/s00432-025-06109-w.

Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.

Wang Y, Zhao Y, Liu Q, Yang J, Xu Z, Du W Transl Cancer Res. 2024; 13(10):5178-5189.

PMID: 39525026 PMC: 11543048. DOI: 10.21037/tcr-23-2367.

Hydrogel-based formulations for urothelial cancer therapy.

Chang M, Chi C, Zheng Z, Zhang M, Lv J, Wang X Front Pharmacol. 2024; 15:1478394.

PMID: 39386025 PMC: 11461203. DOI: 10.3389/fphar.2024.1478394.

Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer.

Gao H, Qiu Y, Zheng X, Xu T, Liu G Front Oncol. 2024; 14:1466319.

PMID: 39351351 PMC: 11441374. DOI: 10.3389/fonc.2024.1466319.

A Circadian Rhythm-related Signature to Predict Prognosis, Immune Infiltration, and Drug Response in Breast Cancer.

Chu M, Huang J, Wang Q, Fang Y, Cui D, Jin Y Curr Med Chem. 2024; 32(3):608-626.

PMID: 39279697 DOI: 10.2174/0109298673320179240803071001.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Meeks J, Lerner S . Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell. 2017; 32(5):550-551. DOI: 10.1016/j.ccell.2017.08.015. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

Roupret M, Neuzillet Y, Masson-Lecomte A, Colin P, Comperat E, Dubosq F . [CCAFU french national guidelines 2016-2018 on bladder cancer]. Prog Urol. 2016; 27 Suppl 1:S67-S91. DOI: 10.1016/S1166-7087(16)30704-7. View

Old L, CLARKE D, Benacerraf B . Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959; 184(Suppl 5):291-2. DOI: 10.1038/184291a0. View

Morales A, Eidinger D, Bruce A . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116(2):180-3. DOI: 10.1016/s0022-5347(17)58737-6. View

Sylvester R, Brausi M, Kirkels W, Hoeltl W, da Silva F, Powell P . Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and.... Eur Urol. 2009; 57(5):766-73. PMC: 2889174. DOI: 10.1016/j.eururo.2009.12.024. View

Novara G, Catto J, Wilson T, Annerstedt M, Chan K, Murphy D . Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol. 2015; 67(3):376-401. DOI: 10.1016/j.eururo.2014.12.007. View

10.

Porter M, Penson D . Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005; 173(4):1318-22. DOI: 10.1097/01.ju.0000149080.82697.65. View

11.

Donin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A . Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2016; 197(1):14-22. DOI: 10.1016/j.juro.2016.02.3005. View

12.

Schumacher T, Schreiber R . Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74. DOI: 10.1126/science.aaa4971. View

13.

Pietzak E, Bagrodia A, Cha E, Drill E, Iyer G, Isharwal S . Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur Urol. 2017; 72(6):952-959. PMC: 6007852. DOI: 10.1016/j.eururo.2017.05.032. View

14.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Ribas A . Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015; 373(16):1490-2. DOI: 10.1056/NEJMp1510079. View

17.

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

18.

Nassar A, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen E . Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2018; 25(8):2458-2470. DOI: 10.1158/1078-0432.CCR-18-3147. View

19.

Kawahara T, Ishiguro Y, Ohtake S, Kato I, Ito Y, Ito H . PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urol. 2018; 18(1):97. PMC: 6219206. DOI: 10.1186/s12894-018-0414-8. View

20.

Walton E, Yaguchi G, Keeley J, Deebajah M, Menon M, Peabody J . Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans. J Urol. 2018; 201(3):503-509. DOI: 10.1016/j.juro.2018.10.003. View